ClinicalTrials.gg
RecruitingNCT05315141Updated Apr 7, 2022

Multicenter Cohort Study of AAV in Hunan of China

An observational study in ANCA Associated Vasculitis, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2022-04-07.

Sponsored by Xiangya Hospital of Central South University · Observational

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China — 42 open to participants now, 46 under way, 1 of them phase 3. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China.

Started
2022
with 1 other
Observational
5 of 57
2 open now
Primary completion
2027-03
later than 19 of 45 live
Registered
8th of 57
by date

Among the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China, this one is one of 2 that started in 2022, is one of 5 observational ones, reaches primary completion later than 19 of the 45 other live ones, and was the 8th registered.

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

158 studies on the registry are indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 76 are open to participants now.

Browse Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies →

Open to participants now

42 of the 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 56 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies recruiting now, 21 (38%) set no upper age limit and 28 (50%) stop at 75 or younger; 9 take children under 18; 7 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in China, or all of them as a file.
02

Study summary

This study aimed to explore the incidence of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) progression and its association with adverse consequences. It will enroll approximately 500 AAV patients in Hunan province of China and follow-up for at least 5 years. Demographic characteristics, clinical and laboratory data will be collected at baseline and every follow-up. The principal clinical outcomes of the study consist of end stage renal disease (ESRD) and death.

Read the detailed description

The study is a multicenter prospective cohort study, aimed to explore the incidence of AAV and its progression and association with adverse consequences. The study will establish a baseline cohort of 500 AAV patients in Hunan province of China. The follow-up will be conducted for at least 5 years until death or starting renal replacement therapy or dropout. Their demographic characteristics, clinical data, laboratory and imaging examinations will be collected at baseline and every follow-up.

The baseline visit includes the following items: detailed demographics, medical and family history, medication history, health behaviors, physical activity, and anthropometric measures. The laboratory parameters of chemistry test. After the baseline visit, participants will return annually for follow-up visits and evaluation. The evaluating items of follow-up visits are similar to the baseline visit, and sample collection.

The principal clinical outcomes of the study can be broadly categorized as end stage renal disease and death. Death is further clarified as cardiac, infectious, renal, others, or unknown.

03

Conditions studied

  • ANCA Associated Vasculitis

Keywords

  • ANCA Associated Vasculitis
  • ESRD
  • Outcome
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study enrolled all the AAV patients that fulfill 2012 criteria of ANCA associated vasculitis and agree to sign informed

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fulfill 2012 criteria of ANCA associated vasculitis and agree to sign

Exclusion criteria

Exclusion Criteria:

  • Do not agree to sign
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Xiangya Hospital

    Other: No Intervention

  • The Second Xiangya Hospital

    Other: No Intervention

  • The Third Xiangya Hospital

    Other: No Intervention

  • Hunan Provincial People's Hospital

    Other: No Intervention

  • Xiangtan Central Hospital

    Other: No Intervention

Interventions

  • OtherNo Intervention

    No Intervention

06

What researchers measure

Primary outcomes

  1. Death

    death from any cause

    Time frame: from date of baseline examination until the date of death from any cause, up to 60 months

  2. End stage renal disease or significant loss of renal function

    start of chronic dialysis or renal transplantation or irreversible development of glomerular filtration rate \<15 ml/minute per 1.73m(2)

    Time frame: from date of baseline examination until the date of first documented end stage renal disease or date of death from any cause, whichever came first, up to 60 months

Secondary outcomes

  1. Disease activity

    assessed by the proportion of patients with severe flares

    Time frame: Five years

  2. Adverse events

    a. deaths (from all causes); b. grade 3 or higher infections; c. malignant conditions; d. venous thromboembolic events; e. cardiovascular events; f. hospitalizations

    Time frame: Five years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2022 (actual). Primary completion is estimated for Mar 2027, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2022
First posted
Apr 7, 2022
StartActual
Mar 16, 2022
Primary completionEst.
Mar 16, 2027
CompletionEst.
Mar 16, 2027
Last update
Apr 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05315141
Collaborators
Central South University, The Third Xiangya Hospital of Central South University, Hunan Provincial People's Hospital, Xiangtan Central Hospital
Responsible party
Xiangcheng Xiao (Professor, Xiangya Hospital of Central South University) — Principal investigator
First posted
Apr 7, 2022
Start date
Mar 16, 2022
Primary completion
Mar 16, 2027 (estimated)
Completion
Mar 16, 2027 (estimated)
Last update
Apr 7, 2022

Study contacts

Yong Zhong, doctor
Contact
zhongyong121@163.com
+86073189753025
Ting Meng, doctor
Contact
mengting252@163.com
+86073184327431
Xiangcheng Xiao, doctor
principal investigator · Xiangya Hospital of Central South University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion